Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Bimat + Applicators

Bimat + Applicators
In stock
3ml
from A$68.27
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$68.29A$68.27
A$68.27 per bottle

In brief

  • In some pharmacies and online e‑pharmacies you can buy bimat + applicators without a prescription and with delivery across Australia from certain vendors; however, bimatoprost is classified as prescription‑only in many countries and availability without a prescription depends on the seller and local regulations, so check before purchase.
  • Bimatoprost is used to treat eyelash hypotrichosis (to increase eyelash length, thickness and darkness) and to lower intraocular pressure in glaucoma/ocular hypertension; it is a prostaglandin analogue that stimulates eyelash follicle growth and increases aqueous humour outflow to reduce IOP.
  • The usual dose for eyelash growth is to apply one drop of 0.03% solution to a sterile single‑use applicator and brush along the upper eyelid margin once nightly; for glaucoma the usual dose is one drop into the affected eye(s) once daily.
  • The medicine is supplied as an ophthalmic solution (commonly 0.03% for eyelash use) in small bottles and is intended for topical ocular administration using sterile single‑use applicators supplied with the product.
  • For eyelash growth, visible effects typically begin after about 4 weeks with optimal results around 16 weeks; for glaucoma, intraocular pressure reduction can begin within hours (around 3–4 hours) with peak effect at roughly 8–12 hours.
  • The eyelash‑enhancing effect is maintained only with continued use (stopping treatment reverses gains over time); for glaucoma a once‑daily dose provides approximately 24‑hour IOP control; note that pigmentation changes (eg, iris darkening) can be permanent.
  • There is no specific interaction with alcohol, but avoid alcohol if it increases eye irritation or dryness and take care around procedures; moderate alcohol consumption is not known to affect topical bimatoprost systemic action.
  • The most common side effec is eye or eyelid irritation and redness.
  • Would you like to try bimat + applicators without a prescription?

Critical Warnings, Restrictions & Patient Protection

Basic Bimat + Applicators Information

  • INN (International Nonproprietary Name): Bimatoprost
  • Brand Names Available In Australia: Not specified
  • ATC Code: S01EE03
  • Forms & Dosages: Latisse 0.03% (3 mL, 5 mL with single‑use applicators); Lumigan 0.01%/0.03% (2.5–9 mL bottles); Careprost/Bimat 0.03% (commonly 3 mL) — all ophthalmic solutions listed in international packaging data.
  • Manufacturers In Australia: Not specified
  • Registration Status In Australia: Not specified
  • OTC / Rx Classification: Prescription Only (Rx)

Bimatoprost is a prescription ophthalmic medicine and formulations used for eyelash growth are typically 0.03% while glaucoma preparations range from 0.01% to 0.03%.

Known hypersensitivity to bimatoprost or excipients such as benzalkonium chloride is an absolute contraindication to treatment.

Active ocular infection or inflammation is also a contraindication until the condition is treated and reviewed by an ophthalmologist.

High‑risk groups include pregnant or breastfeeding people who should avoid bimatoprost unless advised by a specialist because safety for cosmetic use is not established.

Children are not recommended to use bimatoprost for cosmetic eyelash growth; glaucoma use in children is specialist‑managed only.

Patients with uveitis, macular oedema, aphakia or pseudophakia with a torn posterior lens capsule require ophthalmologist review before any prostaglandin analogue is started.

Transient blurred vision, stinging or local irritation may occur after instillation; advise patients not to drive or operate heavy machinery until their vision is clear.

In Australia bimatoprost products are prescription‑only; confirm TGA registration and PBS subsidy before prescribing or supplying.

Immediate red‑flag symptoms requiring urgent review include severe eye pain, sudden reduced vision, copious discharge or signs of infection.

For cosmetic eyelash use, pharmacist or ophthalmologist counselling and written informed consent are recommended because iris pigmentation changes can be permanent.

High-Risk Groups

Pregnant or breastfeeding people should avoid bimatoprost for cosmetic use unless a specialist advises otherwise.

Children should not use bimatoprost for eyelash enhancement as safety and efficacy are not established for that indication.

Patients with active ocular inflammation, uveitis or macular oedema need ophthalmology assessment before starting therapy.

People with aphakia or pseudophakia with a torn capsule have increased risk and should be reviewed by an ophthalmologist.

Interaction With Activities

Instilment can cause transient blurred vision or photophobia so patients must not drive or operate heavy machinery until vision has returned to normal.

Advise patients in safety‑critical or safety‑sensitive workplaces to avoid instillation before duties where visual acuity is essential and to inform their employer if relevant.

Q&A — “Can I Drive After Taking It In Australia?”

If your vision is blurred or you feel dizzy or light‑sensitive after instillation, do not drive or operate heavy machinery.

Most effects are transient; wait until vision returns to normal.

If any vision change persists, seek urgent ophthalmology review.

Usage Basics: INN, Brand Names & Legal Classification

INN, Brand Names Available In Australia

INN: bimatoprost is the active ingredient in both eyelash‑growth and glaucoma formulations.

International brands and generics include Latisse (typically 0.03% and supplied with single‑use applicators), Lumigan (0.01% or 0.03% ophthalmic solutions), and generics such as Careprost/Bimat often sold as 0.03% products.

Packaging differs by market; eyelash products are commonly supplied with sterile single‑use applicators to reduce infection risk.

Legal Classification (TGA‑Approved, PBS‑Listed)

Bimatoprost is classified as a prescription‑only medicine in most jurisdictions according to international data, and Australian supply should follow TGA and PBS rules for the specific product.

Check the ARTG entry and the PBS schedule before prescribing to confirm indication‑specific subsidy and any prescribing restrictions.

Brand Concentration Pack Sizes Typical Rx Status
Latisse 0.03% 3 mL, 5 mL with ~60+ applicators Prescription Only
Lumigan 0.01% / 0.03% 2.5 mL–9 mL bottles Prescription Only
Careprost / Bimat 0.03% 3 mL, 5 mL Prescription Only (varies by market)

Clinicians should verify the product SPC for concentrations and excipients such as benzalkonium chloride before supply.

Dosing Guide: Standard Regimens & Adjustments

Standard Regimens (PBS Reference Dosing)

For eyelash hypotrichosis the usual regimen is one application nightly: apply one drop of 0.03% to a single‑use sterile applicator and stroke along the upper eyelid margin once nightly.

For glaucoma or ocular hypertension the standard adult dose is one drop into the affected eye(s) once daily, either morning or evening but not both.

Do not double doses if a dose is missed; for glaucoma try to maintain daily timing.

Adjustments For Comorbidities

Children: cosmetic use is not recommended; glaucoma dosing in children requires specialist oversight.

Elderly: no routine dose adjustment but monitor ocular surface, IOP response and tolerability.

Renal or hepatic impairment: systemic exposure is minimal and specific dose adjustments are not established; use with caution and monitor for systemic symptoms.

Once Nightly Application
Apply to the upper eyelid margin with a sterile single‑use applicator only once each night for cosmetic lash treatment.
Once Daily Drop
Instil one drop into the conjunctival sac of the affected eye(s) once daily for glaucoma management.
  • Confirm indication (cosmetic versus glaucoma) before dispensing.
  • Provide or confirm single‑use applicators are supplied and counsel never to reuse or share applicators.
  • Advise patients not to double doses and to store bottles between 2–25°C away from heat and light.
  • Contact lens users should remove lenses before instillation and wait at least 15 minutes before reinserting.
  • Consider baseline photography for cosmetic treatment to document iris colour and periocular appearance.

Q&A — “What If I Miss A Dose?”

If you miss a dose, apply the next dose at the usual scheduled time and do not double up.

For glaucoma maintain daily timing where possible and contact the prescriber if multiple doses were missed.

Interaction Chart: Drugs, Food & Workplace Factors

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Systemic interactions with food or alcohol are minimal because topical bimatoprost has low systemic absorption.

Alcohol may increase ocular redness or irritation in some patients but does not change the drug’s mechanism of action.

Caffeine or typical Australian dietary factors do not alter topical bimatoprost effects in clinical data provided.

Common Drug Conflicts

Concurrent use of multiple topical prostaglandin analogues is not recommended due to additive local effects and increased irritation.

Topical beta‑blocker eye drops may be used in combination as part of a glaucoma regimen depending on target intraocular pressure; follow ophthalmologist guidance.

Patients on systemic immunosuppressants or with active ocular inflammation should be reviewed before starting bimatoprost.

Substance/Drug Interaction/Risk Action (Australian Practice)
Other Prostaglandin Analogues (topical) Additive ocular irritation, uncertain benefit Avoid concurrent topical prostaglandins; consult ophthalmologist
Topical Beta‑Blockers (e.g., timolol) Used together for additive IOP lowering in glaucoma Use under ophthalmologist supervision; monitor IOP and tolerability
Systemic Immunosuppressants Higher risk with active ocular inflammation Assess ocular surface and inflammatory status before use
  • Avoid instilling drops immediately before safety‑critical work if transient blurred vision is expected.
  • Workers in safety‑sensitive roles should report temporary visual effects to their employer if required by workplace policy.

User Reports & Trends

Many Australian patients report visible lash lengthening between four and sixteen weeks, which aligns with clinical expectations for bimatoprost eyelash products.

Common consumer complaints include eyelid or ocular irritation, concerns about applicator sterility if applicators are not single‑use, and reports of periocular or iris pigmentation changes.

Pharmacy counselling notes and product review sites reflect a mix of high cosmetic satisfaction and concern over potential permanent pigmentation.

  • Efficacy Timeline: first effects often noted at ~4 weeks with peak or optimal appearance by ~16 weeks.
  • Side‑Effect Frequency: irritation and redness are the most commonly reported adverse events.
  • Safety Concerns: pigmentation of the iris or periocular skin can be permanent and is a frequent reason for counselling.
Outcome Reported Rate Notes
Reporting Improvement Not specified — use clinic/study data Refer to published trials or local audit for exact percentages
Reporting Irritation Not specified — use clinic/study data Frequency varies by formulation and preservative content
Reporting Pigmentation Not specified — use clinic/study data Pigmentation may be permanent; baseline photos recommended

Trend note: telehealth‑driven prescribing for cosmetic use has increased and pharmacists are fielding more questions about eyebrow use off‑label.

Access & Purchase Options In Australia

National Chains (Chemist Warehouse, Priceline, TerryWhite)

Bimatoprost products are supplied through community pharmacies, including major chains and specialist ophthalmology clinics, but are prescription‑only in most jurisdictions.

Cosmetic eyelash formulations are usually supplied privately and are typically not PBS‑subsidised.

Online Pharmacies And Telehealth E‑Prescriptions

Purchase routes include local pharmacy with a prescription, specialist ophthalmology clinic supply, or online pharmacy with a valid e‑prescription or telehealth consultation.

In our online pharmacy, bimat + applicators is available without a prescription, with discreet delivery to Australia in 9-21 days.

Source Typical Wait Time Likely Cost PBS Eligibility
Local Community Pharmacy (chain/independent) Same day to 2 days if stocked Varies by brand Glaucoma indications may be PBS‑listed; cosmetic use usually not subsidised
Specialist Ophthalmology Clinic Same day at clinic Private supply fees may apply Depends on indication and product
Online Pharmacy With E‑Prescription 2–14 days (depends on courier) Varies; shipping adds cost As above
  • Rural patients: check local pharmacy stock, arrange courier delivery, and book teleophthalmology or outreach follow‑up if needed.
  • Avoid overseas suppliers that do not include sterile single‑use applicators or lack Australian regulatory oversight.

Mechanism Of Action & Pharmacology

Simplified Explanation

Bimatoprost is a prostaglandin analogue that increases aqueous humour outflow to lower intraocular pressure and prolongs the anagen phase of hair follicles to stimulate lash growth.

Topical nightly application to the upper eyelid margin encourages lashes to grow longer, thicker and darker over weeks to months.

Clinical Terms & Implications

Anagen Phase
The active growth phase of a hair follicle during which cells divide rapidly and hair length increases.
Prostaglandin Analogue
A class of compounds that mimic prostaglandin activity and affect ocular physiology and hair follicles.
Ocular Hypotension
Reduction in intraocular pressure achieved by increased aqueous outflow.

The same pharmacological action that promotes eyelash growth accounts for adverse effects such as iris and periocular skin pigmentation and possible changes in lash direction.

Document baseline iris colour and ocular surface status before initiating bimatoprost for either glaucoma or cosmetic use.

Indications & Off‑Label Uses In Australian Clinical Practice

Approved Indications By TGA

Internationally bimatoprost is licensed for glaucoma/ocular hypertension and for hypotrichosis in specific formulations; check the TGA ARTG listing for the Australian registration and approved indications for the chosen product.

Many eyelash growth formulations are 0.03% and packaged with single‑use applicators but may be marketed differently depending on the jurisdiction.

Off‑Label Uses And Clinician Considerations

Off‑label uses such as eyebrow enhancement are increasingly reported but clinicians must document informed consent and baseline appearance.

  • Confirm the indication and discuss risks and benefits in clear terms.
  • Ensure single‑use applicators are provided to reduce infection risk.
  • Schedule follow‑up and advise patients to report pigmentation or visual symptoms promptly.
  • Report adverse events to the TGA as required.

Key Clinical Findings & Evidence

Topical bimatoprost reliably increases eyelash length, thickness and darkness with initial effects at around four weeks and optimal results by about sixteen weeks.

For glaucoma, bimatoprost lowers intraocular pressure effectively and is used alone or in combination depending on target IOP and patient factors.

Common mild adverse events include ocular irritation and redness while pigmentary changes to the iris and periocular skin are less common but may be permanent.

Endpoint Typical Result Common Adverse Events
Efficacy Onset ~4 weeks for lashes Irritation, redness
Peak Effect ~16 weeks for lashes Periocular/iris pigmentation (may be permanent)
Glaucoma IOP Lowering Effective at 0.01%–0.03% concentrations Ocular surface discomfort
  • Monitoring recommendations: baseline IOP if used for glaucoma, baseline photos for cosmetic use, and regular follow‑up to detect pigmentation or inflammatory changes.
  • Refer to systematic reviews and local ophthalmology guidelines for up‑to‑date comparisons with latanoprost and travoprost.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Product Indication Concentration Evidence Strength PBS Status Key Pros/Cons
Latisse Hypotrichosis (eyelashes) 0.03% Strong for lash growth Not typically PBS‑subsidised for cosmetic use Effective but risk of pigmentation; prescription required
Lumigan Glaucoma / OHT 0.01% / 0.03% Strong for IOP lowering May be PBS‑listed for glaucoma Effective for IOP; similar class adverse effects
OTC Lash Serums (Peptide‑based) Cosmetic Varies Limited evidence Not PBS‑subsidised Lower proven efficacy; fewer pigmentation risks reported

Pros And Cons Checklist

  • Efficacy: bimatoprost has robust evidence for lashes; OTC serums have limited data.
  • Safety: risk of permanent pigmentation with bimatoprost is a key concern.
  • Cost: cosmetic uses are typically out‑of‑pocket while glaucoma indications may receive PBS subsidy.
  • Ongoing Use: benefits require continued application to maintain results.
  • Applicators: single‑use applicators are a safety advantage for bimatoprost formulations.

Common Questions From Australian Pharmacy Consultations

  • Is a prescription required? Yes — bimatoprost products are prescription‑only in most cases; verify the product and local rules.
  • How long till lashes show? Many patients see change around 4 weeks with optimal results by 16 weeks.
  • Are applicators really single‑use? Yes — never share or reuse single‑use applicators to prevent infection.
  • Will it change my iris colour? Iris darkening can occur and may be permanent; advise patients before starting.
  • Can I use with contact lenses? Remove lenses before application and wait at least 15 minutes before reinserting.
  • Is it PBS subsidised? Cosmetic uses are usually not subsidised; glaucoma indications may be eligible — check PBS schedule.
  • What should pharmacists document? Record counselling, offer baseline photos, provide written patient information and arrange follow‑up.

Offer a follow‑up call or pharmacy check at 4–8 weeks to assess tolerability and early effect.

Price & Access Comparison

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Source Typical Price (AUD) PBS Subsidy Prescription Required Notes
Chemist Warehouse / Priceline / TerryWhite Varies by brand Cosmetic: No; Glaucoma: Possibly Yes Check local stock and brand availability
Online Pharmacy with E‑Rx Varies; shipping additional As above Yes (e‑prescription) Courier options for rural patients
Specialist Clinic Private supply fees Depends on indication Yes Immediate provision often available at clinic

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

  • Confirm whether the chosen product is stocked by the local pharmacy before arranging a visit.
  • Offer couriered delivery and advise on storage during transit for rural patients.
  • Verify that the product includes single‑use applicators and that labelling complies with ARTG requirements.
  • Warn patients about unregulated overseas purchases that may lack sterility or correct labelling.

Registration, Regulation & Reporting

TGA Approval

Always verify the ARTG/TGA listing for the specific bimatoprost product before prescribing or dispensing in Australia.

International brand indications differ — confirm whether the product is approved locally for hypotrichosis or glaucoma.

PBS Subsidy Details & Adverse Event Reporting

Cosmetic eyelash use is typically not PBS‑subsidised while glaucoma indications may qualify depending on product and indication.

Suspected serious adverse events such as severe ocular inflammation or permanent iris pigmentation should be reported to the TGA Adverse Event Management System.

  • Verify ARTG entry for the exact brand and batch if supplying an imported product.
  • Confirm PBS item number and prescribing authority requirements where relevant.
  • Provide patients with TGA adverse event reporting information and document any reports made.

Storage & Handling

Household Storage In Australian Climate (Heat/Humidity)

Store bimatoprost between 2–25°C and protect from heat and light as per product data.

Advise patients not to leave bottles in cars or exposed to direct sunlight, especially during hot Australian summers.

Do not use after expiry or if the solution discolours or becomes cloudy.

Cold‑Chain Handling For Pharmacies

Pharmacies should store stock within the recommended temperature range, using air‑conditioned storage where necessary.

For couriered supplies to rural areas use insulated packaging when ambient temperatures exceed recommended storage limits and label packages with storage instructions.

  • Check expiry dates at dispense and confirm single‑use applicators are in the pack.
  • Advise on safe disposal of used applicators and empty bottles.

Guidelines For Proper Use & Pharmacist Counselling Style

Australian Pharmacist Counselling Checklist

Confirm the indication: cosmetic eyelash use versus glaucoma management.

Review absolute contraindications such as known hypersensitivity to bimatoprost or benzalkonium chloride and active ocular infection.

Explain dosing clearly: eyelash use = apply nightly to upper eyelid margin with a sterile applicator; glaucoma = one drop once daily.

Emphasise single‑use applicators — never reuse or share applicators to avoid infection risk.

Discuss potential risks including permanent iris pigmentation, periocular skin darkening and common transient irritation.

Provide storage advice and what to do if a dose is missed or if symptoms of infection or severe inflammation occur.

Offer baseline photographs for cosmetic use and schedule follow‑up at 4–16 weeks depending on the indication.

  • Document informed consent for cosmetic supply and record counselling in the patient file.
  • Provide a written handout summarising dosing, storage, red‑flag symptoms and adverse event reporting details.
  • Encourage patients to report side effects and to seek urgent care for severe pain or sudden vision loss.

Patient Advice From PBS And National Health Authorities

Advise patients that cosmetic use is usually not PBS‑funded and that glaucoma treatments may have different subsidy and prescribing rules.

Recommend reporting adverse effects and ensure patients know how to contact the prescribing clinician or a local ophthalmology service if problems arise.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Hobart Tasmania 9-14 days
Darwin Northern Territory 9-14 days
Gold Coast Queensland 14-21 days
Newcastle New South Wales 14-21 days
Wollongong New South Wales 14-21 days
Sunshine Coast Queensland 14-21 days
Geelong Victoria 14-21 days
Townsville Queensland 14-21 days
Cairns Queensland 14-21 days

Related products